A detailed history of Act Capital Management, LLC transactions in Inhibikase Therapeutics, Inc. stock. As of the latest transaction made, Act Capital Management, LLC holds 937,500 shares of IKT stock, worth $2.26 Million. This represents 1.18% of its overall portfolio holdings.

Number of Shares
937,500
Previous 937,500 -0.0%
Holding current value
$2.26 Million
Previous $696,000 22.56%
% of portfolio
1.18%
Previous 0.97%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.63 - $1.44 $87,570 - $200,160
-139,000 Reduced 12.91%
937,500 $696,000
Q4 2021

Feb 03, 2022

BUY
$1.38 - $2.17 $91,770 - $144,305
66,500 Added 6.58%
1,076,500 $1.58 Million
Q3 2021

Nov 16, 2021

BUY
$1.79 - $2.81 $241,650 - $379,350
135,000 Added 15.43%
1,010,000 $1.92 Million
Q2 2021

Aug 16, 2021

BUY
$2.8 - $6.23 $2.45 Million - $5.45 Million
875,000 New
875,000 $2.45 Million

Others Institutions Holding IKT

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0

About Inhibikase Therapeutics, Inc.


  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $60.8M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Act Capital Management, LLC Portfolio

Follow Act Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Act Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Act Capital Management, LLC with notifications on news.